December 10th Glioblastoma Drug Development Summit

Looks like our fearless CEO is going to be busy at the 2nd Annual Glioblastoma Drug Development Summit

https://glioblastoma-drugdevelopment.com/about/agenda/day-two/

11:00 am PANEL DISCUSSION: Recognize the Financial Difficulty of Developing Glioblastoma Treatments and Moving Drugs to the Next Phase

• James GarnerChief Executive Officer & Managing Director, Kazia Therapeutics Limited
• Petra HamerlikAssociate Research Director/Bioscience, AstraZeneca
• Ranjit S. BindraAssociate Professor of Therapeutic Radiology, Yale School of Medicine
• Linda LiauChair of Neurosurgery, UCLA

Synopsis

• Explore the challenges of funding development
• How can drug developers inspire and attract companies to invest in their novel preclinical glioblastoma development and pipeline?
• How can the industry come together to overcome the paucity of funding?

1:45 pm Study PI3K as a Key Target in Glioblastoma

• James GarnerChief Executive Officer & Managing Director, Kazia Therapeutics Limited

Synopsis

• Explore opportunities and challenges associated with modulating PI3K
  as a therapeutic strategy in glioblastoma
• Examine The significance of biomarkers in patient selection
• Review emerging clinical data from paxalisib, a brain penetrant PI3K /
  mTOR inhibitor

3:30 pm Realizing Potential: Taking GDC-0084 Forward in Glioblastoma

• James GarnerChief Executive Officer & Managing Director, Kazia Therapeutics Limited

Synopsis

• Identifying a target population: newly-diagnosed versus recurrent patients
• Addressing the challenges and opportunities in designing a definitive clinical proof-of-concept for GBM
• Defining a path-to-market for GDC-0084
• Establishing the commercial prospects for a new drug in GBM

I particularly like this 3.30pm session, maybe Friday 11th December will be a good day for us on the ASX.